- Previous Close
110,900.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 130,000.00 - Volume
0 - Avg. Volume
301,103 - Market Cap (intraday)
8.638T - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jan 27, 2025 - Jan 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
123,642.86
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
www.skbp.comRecent News: 326030.KS
View MorePerformance Overview: 326030.KS
Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 326030.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 326030.KS
View MoreValuation Measures
Market Cap
8.68T
Enterprise Value
8.59T
Trailing P/E
151.50
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.98
Price/Book (mrq)
25.70
Enterprise Value/Revenue
16.81
Enterprise Value/EBITDA
118.61
Financial Highlights
Profitability and Income Statement
Profit Margin
7.27%
Return on Assets (ttm)
3.47%
Return on Equity (ttm)
7.41%
Revenue (ttm)
465.06B
Net Income Avi to Common (ttm)
33.8B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
286.45B
Total Debt/Equity (mrq)
55.51%
Levered Free Cash Flow (ttm)
-15.35B